The French group Sanofi has partnered research and an option for a licensing agreement with the Scottish Exscientia startups in the field of metabolic diseases such as diabetes, said Tuesday the sapling in a statement.
Exscientia specializes in the discovery and design of drugs through the use of artificial intelligence.
In this partnership, the company will bring its platform for identification and validation of combinations of drug target pairs, before selecting those that seem most promising for Sanofi, the statement said.
Subsequent trials, preclinical testing will be supported by Sanofi, which can exercise the license option.
This agreement includes an initial research payment and milestone payments. In total, the amount potentially payable by Sanofi amounts to 250 million euros, the statement said.